<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03267498</url>
  </required_header>
  <id_info>
    <org_study_id>162010</org_study_id>
    <secondary_id>NCI-2017-02291</secondary_id>
    <nct_id>NCT03267498</nct_id>
  </id_info>
  <brief_title>Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)</brief_title>
  <official_title>Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sue Yom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National University Cancer Institute, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well nivolumab and chemoradiotherapy works in treating&#xD;
      patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab,&#xD;
      may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the&#xD;
      combination of chemotherapy and radiation therapy and may prevent the cancer from spreading&#xD;
      when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in&#xD;
      treating patients with stage II-IVB nasopharyngeal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To establish the feasibility of treatment completion of a combined&#xD;
      chemoradiation-nivolumab regimen followed by adjuvant nivolumab.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall response rate at 1 year from completion of therapy, as determined&#xD;
      by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.&#xD;
&#xD;
      II. To determine the locoregional control rate at 1 year post-treatment. III. To determine&#xD;
      the distant metastasis rate at 1 year post-treatment. IV. To determine the overall survival&#xD;
      rate at 1 year post-treatment. V. To determine the rate of Epstein-Barr virus (EBV)&#xD;
      deoxyribonucleic acid (DNA) clearance at end of chemoradiation and at 1 year post-treatment.&#xD;
&#xD;
      VI. To assess patients' quality of life from baseline through 1 year post-treatment.&#xD;
&#xD;
      VII. To determine the acute and late toxicity rates according to Common Terminology Criteria&#xD;
      for Adverse Events (CTCAE) version (v.) 5, including immune-related adverse events (AEs).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive nivolumab intravenously (IV) over 60 minutes on day 1 of courses 1-5 and&#xD;
      7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy once daily&#xD;
      (QD) 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats&#xD;
      every 7 days for up to 3 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 100 days, at 1, 3, 6, 9,&#xD;
      and 12 months for up to 1 year, and then every 3 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm, open label clinical trial of concurrent and adjuvant nivolumab, including a run-in phase to establish basic feasibility of the nivolumab schedule followed by expansion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of completion of all adjuvant immunotherapy</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The rate of completion of all adjuvant therapy by patients treated at the maximum tolerated dose (MTD) schedule will be determined and compared to a historical control rate of 52%, the rate of completion of a standard adjuvant cisplatin-based platform to determine feasibility of study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 1 year after completion of treatment</time_frame>
    <description>The ORR is based on the best overall response (BOR) recorded from the first day of treatment until time of assessment. The percentages of patients with a best overall response rate of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be determined as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-related Adverse Events (AEs)</measure>
    <time_frame>Up to 1 year after completion of treatment</time_frame>
    <description>Adverse events will be classified using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) version 5.0 by the investigator assessment and reported by</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional Control (LRC) Rate</measure>
    <time_frame>Up to 1 year after completion of treatment</time_frame>
    <description>Duration of LRC will be calculated as 1+ the number of days from the first day of treatment to time of documented locoregional clinical or radiographic relapse, progression or death due to any cause. For patients who continue treatment post-progression, the date of clinical or radiographic relapse or progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean LRC rate with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis (DM) Rate</measure>
    <time_frame>Up to 1 year after completion of treatment</time_frame>
    <description>Time to DM will be calculated as 1+ the number of days from the first day of treatment to documented clinical or radiographic progression at a distant metastatic site, or death due to any cause. Pathologic confirmation is not required to document the date of distant progression. For patients who continue treatment post-progression, the date of clinical or radiographic progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean DM rate with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate (OSR)</measure>
    <time_frame>Up to 1 year after completion of treatment</time_frame>
    <description>OSR will be calculated as the time from first treatment until death by any cause, or study closure - whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scores on the Functional Assessment of Cancer Therapy - Nasopharyngeal Cancer (FACT-NP)</measure>
    <time_frame>Up to 1 year after completion of treatment</time_frame>
    <description>The FACT-NP is a self-report instrument that measures multidimensional quality of life (QOL) in patients with Nasopharyngeal cancer-specific scale. The FACT-NP consists of 43 questions that address physical, social, emotional, and functional well-being, with additional specific questions relevant to persons with nasopharyngeal cancers. Each item has a score range of 0 (Not at all) to 4 (Very much). For the 37 general health and head and neck cancer sections, the raw score range is 0-148, with the higher scores indicating better QOL reported by the participant. The 6 remaining questions for the nasopharyngeal cancers also fall on the same range of 0 to 4, with a raw total score range of 0-24, but on this subscale, lower scores indicate a higher QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with acute toxicities</measure>
    <time_frame>Up to 1 year after completion of treatment</time_frame>
    <description>Acute toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Late toxicities</measure>
    <time_frame>Up to 1 year after completion of treatment</time_frame>
    <description>Late toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab + chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.</description>
    <arm_group_label>Nivolumab + chemoradiation</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.</description>
    <arm_group_label>Nivolumab + chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday</description>
    <arm_group_label>Nivolumab + chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females ≥18 years of age.&#xD;
&#xD;
          2. Histologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by&#xD;
             American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World&#xD;
             Health Organization (WHO) type 2a and 2b nonkeratinizing or undifferentiated subtypes,&#xD;
             excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within&#xD;
             90 days of registration.&#xD;
&#xD;
          3. Positron emission tomography-computed tomography (PET-CT) (preferred) or a CT of&#xD;
             chest, abdomen, and pelvis within 60 days of registration showing radiographic stage&#xD;
             II to IVB nasopharyngeal cancer.&#xD;
&#xD;
          4. No distant metastasis as verified by one of the study investigators.&#xD;
&#xD;
          5. Documentation that the patient is a candidate for chemoradiation of their&#xD;
             nasopharyngeal cancer by one of the study investigators.&#xD;
&#xD;
          6. Ability to tolerate radiation therapy (e.g. lie flat and hold position for treatment).&#xD;
&#xD;
          7. Measurable disease as defined by RECIST v1.1.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          9. Lack of contraindications to systemic immunotherapy (see list of exclusions below).&#xD;
&#xD;
         10. Resolution of all acute toxic effects of any prior chemotherapy, radiotherapy or&#xD;
             surgical procedures to NCI CTCAE Version 5.0 grade 1.&#xD;
&#xD;
         11. Adequate hepatic, hematologic, and renal indices permitting administration of&#xD;
             cisplatin and nivolumab (within 14 days of registration):&#xD;
&#xD;
             Hepatic Function:&#xD;
&#xD;
             Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit&#xD;
             of normal (ULN); Total bilirubin ≤ 1.5 × ULN (except subjects with Gilbert Syndrome,&#xD;
             who can have total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
             Adequate bone marrow function:&#xD;
&#xD;
             White blood cells (WBC) ≥ 2000/μL Neutrophils ≥ 1500/μL Platelet ≥ 100 x103/μL&#xD;
             Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
             Adequate renal function:&#xD;
&#xD;
             Serum creatinine ≤ 1.5 × upper limit of normal (ULN) OR&#xD;
&#xD;
             Creatinine clearance (CrCl) &gt; 40 mL/min (or &gt; 50 mL/min for Singapore sites only) (if&#xD;
             using the Cockcroft-Gault formula below):&#xD;
&#xD;
             Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in&#xD;
             mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in&#xD;
             mg/dL&#xD;
&#xD;
         12. Women of childbearing potential must have a negative serum pregnancy test within 24&#xD;
             hours prior to the first dose of study treatment and agree to use appropriate highly&#xD;
             effective methods of contraception, during the study and for 5 months following&#xD;
             completion of study treatment; A &quot;Woman of childbearing potential&quot; is defined as any&#xD;
             female who has experienced menarche and who has not undergone surgical sterilization&#xD;
             (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is&#xD;
             defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of&#xD;
             other biological or physiological causes. In addition, women under the age of 62 must&#xD;
             have a documented serum follicle stimulating hormone (FSH) level less than 40&#xD;
             milli-international units per milliliter (mIU/mL).&#xD;
&#xD;
             Female Subjects:&#xD;
&#xD;
             Women of child bearing potential are expected to use one of the highly effective&#xD;
             methods of contraception listed in the protocol.&#xD;
&#xD;
             Male Subjects:&#xD;
&#xD;
             Male subjects must inform their female partners who are women of child bearing&#xD;
             potential of the contraceptive requirements and are expected to adhere to using&#xD;
             contraception with their partner. Female partners of male subjects, who are women of&#xD;
             child bearing potential, are expected to use one of the highly effective methods of&#xD;
             contraception listed in the protocol. In addition, male subjects are expected to use a&#xD;
             condom as noted in the protocol.&#xD;
&#xD;
         13. Men with a female partner of childbearing potential must agree to use highly effective&#xD;
             methods of contraception or any contraceptive method with a failure rate of less than&#xD;
             1% per year during the study and for 7 months following completion of study treatment.&#xD;
&#xD;
         14. Ability to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active second malignancy, i.e. patient known to have potentially fatal hematologic&#xD;
             malignancy or another solid primary tumor present for which he/she may be (but not&#xD;
             necessarily) currently receiving treatment. Patients with a prior or concurrent&#xD;
             malignancy whose natural history or treatment does not have the potential to interfere&#xD;
             with the safety or efficacy assessment of the investigational regimen are allowed to&#xD;
             enroll in this trial. For example, patients with early-stage skin cancers, prostate&#xD;
             cancer under surveillance with non-rising prostate-specific antigen (PSA), or&#xD;
             meningioma or thyroid papillary cancers which are under surveillance are eligible. For&#xD;
             determinations of a specific clinical condition, please consult with the Principal&#xD;
             Investigator.&#xD;
&#xD;
          2. Active, untreated central nervous system (CNS) metastases;&#xD;
&#xD;
          3. Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or PD&#xD;
             Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2), anti-cytotoxic T-lymphocyte-associated&#xD;
             protein-4 (CTLA-4) antibody, or any other antibody or drug specifically targeting&#xD;
             T-cell costimulation or immune checkpoint pathways, or cancer vaccine;&#xD;
&#xD;
          4. Prior systemic cytotoxic therapy, antineoplastic biologic therapy, or major surgery&#xD;
             within 28 days of first dose of study medication;&#xD;
&#xD;
          5. Severe hypersensitivity reaction to treatment during prior administration of a&#xD;
             monoclonal antibody (mAb) or history of allergy to any study drug component;&#xD;
&#xD;
          6. Has received a live-virus vaccination within 30 days of planned treatment start;&#xD;
&#xD;
          7. Condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 14 days of study&#xD;
             drug administration; Inhaled or topical steroids and adrenal replacement doses &gt; 10 mg&#xD;
             daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          8. Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior&#xD;
             history of ILD or pneumonitis requiring oral or IV glucocorticoids;&#xD;
&#xD;
          9. Active, known, or suspected autoimmune disease or any autoimmune condition that has&#xD;
             required systemic treatment in the past 2 years (replacement therapies for hormone&#xD;
             deficiencies are allowed); Subjects are permitted to enroll if they have vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger.&#xD;
&#xD;
         10. Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI)&#xD;
             obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation);&#xD;
&#xD;
         11. Signs or symptoms of infection within 2 weeks prior to first day of study treatment.&#xD;
&#xD;
         12. Patients with active tuberculosis (clinical evaluation in line with local practice),&#xD;
             or a known history of active tuberculosis that in the opinion of the treating&#xD;
             investigator has a high risk of reactivation.&#xD;
&#xD;
         13. Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study&#xD;
             treatment: Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract&#xD;
             infection or chronic obstructive pulmonary disease exacerbation) are eligible.&#xD;
&#xD;
         14. Known positive test for human immunodeficiency virus (HIV);&#xD;
&#xD;
         15. Known active hepatitis B or hepatitis C virus (HBV or HCV): Patients with past or&#xD;
             resolved HBV infection (defined by a negative hepatitis B surface antigen (HBsAg) test&#xD;
             and a positive anti-hepatitis B core antigen (HBc) (anti-HBc)antibody test) are&#xD;
             eligible. HBV DNA must be obtained in these patients prior to first day of study&#xD;
             treatment. Patients who have been recently discovered to have HBV with positive HBsAg&#xD;
             test and positive anti-HBc antibody test but who have been started on antiretroviral&#xD;
             treatment with nondetectable HBV DNA are eligible. HBV DNA must be obtained in these&#xD;
             patients prior to first day of study treatment&#xD;
&#xD;
         16. Patients with known active hepatitis C virus ribonucleic acid (HCV antibody)&#xD;
             indicating acute or chronic infection: Patients positive for HCV antibody are eligible&#xD;
             only if Polymerase chain reaction (PCR) test is negative for HCV RNA.&#xD;
&#xD;
         17. Prior radiation therapy of any type within 7 days of first dose of study medication;&#xD;
&#xD;
         18. Prior radiation therapy to head and neck region that would overlap with intended&#xD;
             radiation treatment for nasopharyngeal carcinoma;&#xD;
&#xD;
         19. Medical contraindication to radiation treatment (e.g. active systemic sclerosis, other&#xD;
             uncontrolled autoimmune condition)&#xD;
&#xD;
         20. Treatment with prohibited medications (including concurrent anticancer therapy&#xD;
             including chemotherapy, radiation, hormonal treatment [except corticosteroids and&#xD;
             megestrol acetate] ≤ 14 days prior to treatment.&#xD;
&#xD;
         21. Pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study;&#xD;
&#xD;
         22. Active, uncontrolled psychiatric disorders or substance (drug/alcohol) abuse that&#xD;
             interfere with patient's safety, ability to provide informed consent, or ability to&#xD;
             comply with the protocol.&#xD;
&#xD;
         23. Persons who are incarcerated or otherwise under compulsory detention by an authority&#xD;
             are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue S Yom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>August 22, 2023</last_update_submitted>
  <last_update_submitted_qc>August 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Sue Yom</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03267498
org study id: 162010
secondary id: NCI-2017-02291
nct id: NCT03267498
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This phase II trial studies how well nivolumab and chemoradiotherapy works in treating
      patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab,
      may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the
      combination of chemotherapy and radiation therapy and may prevent the cancer from spreading
      when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in
      treating patients with stage II-IVB nasopharyngeal cancer.
PRIMARY OBJECTIVES:

      I. To establish the feasibility of treatment completion of a combined
      chemoradiation-nivolumab regimen followed by adjuvant nivolumab.

      SECONDARY OBJECTIVES:

      I. To determine the overall response rate at 1 year from completion of therapy, as determined
      by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

      II. To determine the locoregional control rate at 1 year post-treatment. III. To determine
      the distant metastasis rate at 1 year post-treatment. IV. To determine the overall survival
      rate at 1 year post-treatment. V. To determine the rate of Epstein-Barr virus (EBV)
      deoxyribonucleic acid (DNA) clearance at end of chemoradiation and at 1 year post-treatment.

      VI. To assess patients' quality of life from baseline through 1 year post-treatment.

      VII. To determine the acute and late toxicity rates according to Common Terminology Criteria
      for Adverse Events (CTCAE) version (v.) 5, including immune-related adverse events (AEs).

      OUTLINE:

      Patients receive nivolumab intravenously (IV) over 60 minutes on day 1 of courses 1-5 and
      7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or
      unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy once daily
      (QD) 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats
      every 7 days for up to 3 courses in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up for 100 days, at 1, 3, 6, 9,
      and 12 months for up to 1 year, and then every 3 months for 1 year.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Single-arm, open label clinical trial of concurrent and adjuvant nivolumab, including a run-in phase to establish basic feasibility of the nivolumab schedule followed by expansion.
primary purpose: Treatment
masking: None (Open Label)
measure: Rate of completion of all adjuvant immunotherapy
time frame: Up to 1 year
description: The rate of completion of all adjuvant therapy by patients treated at the maximum tolerated dose (MTD) schedule will be determined and compared to a historical control rate of 52%, the rate of completion of a standard adjuvant cisplatin-based platform to determine feasibility of study treatment
measure: Overall response rate (ORR)
time frame: Up to 1 year after completion of treatment
description: The ORR is based on the best overall response (BOR) recorded from the first day of treatment until time of assessment. The percentages of patients with a best overall response rate of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be determined as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
measure: Number of treatment-related Adverse Events (AEs)
time frame: Up to 1 year after completion of treatment
description: Adverse events will be classified using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) version 5.0 by the investigator assessment and reported by
measure: Loco-regional Control (LRC) Rate
time frame: Up to 1 year after completion of treatment
description: Duration of LRC will be calculated as 1+ the number of days from the first day of treatment to time of documented locoregional clinical or radiographic relapse, progression or death due to any cause. For patients who continue treatment post-progression, the date of clinical or radiographic relapse or progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean LRC rate with 95% confidence interval.
measure: Distant Metastasis (DM) Rate
time frame: Up to 1 year after completion of treatment
description: Time to DM will be calculated as 1+ the number of days from the first day of treatment to documented clinical or radiographic progression at a distant metastatic site, or death due to any cause. Pathologic confirmation is not required to document the date of distant progression. For patients who continue treatment post-progression, the date of clinical or radiographic progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean DM rate with 95% confidence interval.
measure: Overall survival rate (OSR)
time frame: Up to 1 year after completion of treatment
description: OSR will be calculated as the time from first treatment until death by any cause, or study closure - whichever occurs first
measure: Change in scores on the Functional Assessment of Cancer Therapy - Nasopharyngeal Cancer (FACT-NP)
time frame: Up to 1 year after completion of treatment
description: The FACT-NP is a self-report instrument that measures multidimensional quality of life (QOL) in patients with Nasopharyngeal cancer-specific scale. The FACT-NP consists of 43 questions that address physical, social, emotional, and functional well-being, with additional specific questions relevant to persons with nasopharyngeal cancers. Each item has a score range of 0 (Not at all) to 4 (Very much). For the 37 general health and head and neck cancer sections, the raw score range is 0-148, with the higher scores indicating better QOL reported by the participant. The 6 remaining questions for the nasopharyngeal cancers also fall on the same range of 0 to 4, with a raw total score range of 0-24, but on this subscale, lower scores indicate a higher QOL.
measure: Percentage of participants with acute toxicities
time frame: Up to 1 year after completion of treatment
description: Acute toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs
measure: Percentage of participants with Late toxicities
time frame: Up to 1 year after completion of treatment
description: Late toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs
arm group label: Nivolumab + chemoradiation
arm group type: Experimental
description: Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
intervention type: Drug
intervention name: Nivolumab
description: Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
arm group label: Nivolumab + chemoradiation
other name: Opdivo
intervention type: Drug
intervention name: Cisplatin
description: Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
arm group label: Nivolumab + chemoradiation
intervention type: Radiation
intervention name: Radiation Therapy
description: 2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
arm group label: Nivolumab + chemoradiation
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Sue S Yom, MD, PhD
role: Principal Investigator
affiliation: University of California, San Francisco
facility: 
facility: 
country: Singapore
country: United States
responsible party type: Sponsor-Investigator
investigator affiliation: University of California, San Francisco
investigator full name: Sue Yom
investigator title: Principal Investigator
mesh term: Carcinoma
mesh term: Nasopharyngeal Carcinoma
mesh term: Nivolumab
sharing ipd: No